Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure

By afschroeder • September 20, 2025

Green L, Armstrong A, Han G, Jacobson A. Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure. Dermatol Ther (Heidelb). 2025 Sep 19. doi: 10.1007/s13555-025-01533-9. Epub ahead of print. PMID: 40971026.

Tags: Biologic failure, Dermatology, ixekizumab, Publications, Quality of Life, Refractory, secukinumab, Therapy switching, tnf inhibitor

Helicobacter pylori as a risk factor for pemphigus and pemphigoid: A US large-scale cohort study using the TriNetX database

Kasperkiewicz M, Ludwig RJ, Curman P. Helicobacter pylori as a risk factor for pemphigus and pemphigoid: A US large-scale cohort study using the TriNetX database.[...]

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial

Ständer S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF. Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial. JAMA[...]

UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes

Chen HC, Bang MF, Wang HH, Shpargel KB, Kohn LA, Sailer D, Zhang S, McCarthy EC, Seyedsadr M, Stevens S, Pham CLH, Zhou Z, Yin[...]